Serum-derived exosomal miR-125a-3p predicts the response to anti-programmed cell death-1/programmed cell death-ligand 1 monotherapy in patients with non-small cell lung cancer-Reference-Cited by-同舟云学术

Serum-derived exosomal miR-125a-3p predicts the response to anti-programmed cell death-1/programmed cell death-ligand 1 monotherapy in patients with non-small cell lung cancer

Published:2023-03 Issue: Volume:857 Page:147177
ISSN:0378-1119
Container-title:Gene
language:en
Short-container-title:Gene

Author:

Hisakane Kakeru,Seike Masahiro,Sugano Teppei,Matsuda Kuniko,Kashiwada Takeru,Nakamichi Shinji,Matsumoto Masaru,Miyanaga Akihiko,Noro Rintaro,Kubota Kaoru,Gemma Akihiko

Publisher

Elsevier BV

Subject

Genetics,General Medicine

Reference42 articles.

1. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer;Borghaei;N. Engl. J. Med.,2015

2. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer;Brahmer;N. Engl. J. Med.,2015

3. UICC TNM Classification of Malignant Tumours;Brierly,2016

4. A novel neuregulin - jagged1 paracrine loop in breast cancer transendothelial migration;Cabrera;Breast Cancer Res.,2018

5. Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling;De Boeck;Gut,2013

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab;Clinical and Experimental Medicine;2024-08-06

2. Immune modulatory microRNAs in tumors, their clinical relevance in diagnosis and therapy;Journal for ImmunoTherapy of Cancer;2024-08

3. Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with Nivolumab;2024-04-22

4. The diagnostic and prognostic value of exosomal microRNAs in lung cancer: a systematic review;Clinical and Translational Oncology;2024-03-15

5. MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways;Cancer Cell International;2024-03-10